Expectancies about the effects of cannabidiol products on anxiety symptoms

References

• Altman, B. R., Mian, M. N., Slavin, M., & Earleywine, M. (2019). Cannabis expectancies for sleep. Journal of Psychoactive Drugs, 51(5), 405–412. https://doi.org/10.1080/02791072.2019.1643053
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.).
   Google Scholar
• Andrade, L. H., Alonso, J., Mneimneh, Z., Wells, J. E., Al-Hamzawi, A., Borges, G., Bromet, E., Bruffaerts, R., De Girolamo, G., De Graaf, R., Florescu, S., Gureje, O., Hinkov, H. R., Hu, C., Huang, Y., Hwang, I., Jin, R., Karam, E. G., Kovess-Masfety, V., Matschinger, H., … Kessler, R. C. (2014). Barriers to mental health treatment: Results from the WHO World Mental Health (WMH) surveys. Psychological Medicine, 44(6), 1303. https://doi.org/10.1017/S0033291713001943
   PubMed Web of Science ®Google Scholar
• Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. Dialogues in Clinical Neuroscience, 19(2), 93–107 https://doi.org/10.31887/DCNS.2017.19.2/bbandelow.
   PubMed Web of Science ®Google Scholar
• Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825–836. https://doi.org/10.1007/s13311-015-0387-1
   PubMed Web of Science ®Google Scholar
• Brown, S. A. (1993). Drug effect expectancies and addictive behavior change. Experimental and Clinical Psychopharmacology, 1(1–4), 55. https://doi.org/10.1037/1064-1297.1.1–4.55
   Web of Science ®Google Scholar
• Bystritsky, A., Khalsa, S. S., Cameron, M. E., & Schiffman, J. (2013). Current diagnosis and treatment of anxiety disorders. Pharmacy and Therapeutics, 38(1), 41–44.
   Google Scholar
• Chartier-Otis, M., Perreault, M., & Bélanger, C. (2010). Determinants of barriers to treatment for anxiety disorders. Psychiatric Quarterly, 81(2), 127–138. https://doi.org/10.1007/s11126-010-9123-5
   PubMed Web of Science ®Google Scholar
• Christiansen, P., Jennings, E., & Rose, A. K. (2016). Anticipated effects of alcohol stimulate craving and impair inhibitory control. Psychology of Addictive Behaviors, 30(3), 383. https://doi.org/10.1037/adb0000148
   PubMed Web of Science ®Google Scholar
• Connor, J. P., Gullo, M. J., Feeney, G. F., & Young, R. M. (2011). Validation of the Cannabis Expectancy Questionnaire (CEQ) in adult cannabis users in treatment. Drug and Alcohol Dependence, 115(3), 167–174. https://doi.org/10.1016/j.drugalcdep.2010.10.025
   PubMed Web of Science ®Google Scholar
• Corroon, J., & Phillips, J. A. (2018). A cross-sectional study of cannabidiol users. Cannabis and Cannabinoid Research, 3(1), 152–161. https://doi.org/10.1089/can.2018.0006
   PubMedGoogle Scholar
• Cougle, J. R., Keough, M. E., Riccardi, C. J., & Sachs-Ericsson, N. (2009). Anxiety disorders and suicidality in the national comorbidity survey-replication. Journal of Psychiatric Research, 43(9), 825–829. https://doi.org/10.1016/j.jpsychires.2008.12.004
   PubMed Web of Science ®Google Scholar
• Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Filho, A. S., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., Hallak, J. E. C., & Simões, M. V. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. Journal of Psychopharmacology, 25(1), 121–130. https://doi.org/10.1177/0269881110379283
   PubMed Web of Science ®Google Scholar
• Crippa, J. A. S., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Frontiers in Immunology, 9, 2009. https://doi.org/10.3389/fimmu.2018.02009
   PubMed Web of Science ®Google Scholar
• Crippa, J. A. S., Zuardi, A. W., Martín‐Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar-Poli, P. (2009). Cannabis and anxiety: A critical review of the evidence. Human Psychopharmacology: Clinical and Experimental, 24(7), 515–523. https://doi.org/10.1002/hup.1048
   PubMed Web of Science ®Google Scholar
• De Mello Schier, A. R., De Oliveira Ribeiro, N. P., Hallak, J. E. C., Crippa, J. A. S., Nardi, A. E., & Zuardi, A. W. (2012). Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Brazilian Journal of Psychiatry, 34 (Supplement 1) , 104–110. https://doi.org/10.1016/S1516-4446(12)70057-0
   Google Scholar
• De Mello Schier, A. R., De Oliveira Ribeiro, P. N., Coutinho, S. D., Machado, S., Arias-Carrión, O., Crippa, A. J., Zuardi, A. W., Nardi, A. E., & Silva, C. A. (2014). Antidepressant-like and anxiolytic-like effects of cannabidiol: A chemical compound of Cannabis sativa. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 13(6), 953–960 https://doi.org/10.2174/1871527313666140612114838.
   PubMed Web of Science ®Google Scholar
• Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., Wong, M., Tilton, N., Bruno, P., Bluvstein, J., Hedlund, J., Kamens, R., Maclean, J., Nangia, S., Singhal, N. S., Patel, A., & Cilio, M. R. (2016). Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. The Lancet Neurology, 15(3), 270–278. https://doi.org/10.1016/S1474-4422(15)00379-8
   PubMed Web of Science ®Google Scholar
• Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy-Byrne, P. P. (2012). Pharmacological treatment of anxiety disorders: Current treatments and future directions. Journal of Anxiety Disorders, 26(8), 833–843. https://doi.org/10.1016/j.janxdis.2012.07.009
   PubMed Web of Science ®Google Scholar
• Friedman-Wheeler, D. G., Ahrens, A. H., Haaga, D. A., McIntosh, E., & Thorndike, F. P. (2007). Depressive symptoms, depression proneness, and outcome expectancies for cigarette smoking. Cognitive Therapy and Research, 31(4), 547–557. https://doi.org/10.1007/s10608-006-9064-3
   PubMed Web of Science ®Google Scholar
• Fromme, K., Stroot, E. A., & Kaplan, D. (1993). Comprehensive effects of alcohol: Development and psychometric assessment of a new expectancy questionnaire. Psychological Assessment, 5(1), 19. https://doi.org/10.1037/1040-3590.5.1.19
   Google Scholar
• Goldman, M. S., Del Boca, F. K., & Darkes, J. (1999). Alcohol expectancy theory: The application of cognitive neuroscience. In K. E. Leonard & H. T. Blane (Eds.), Psychological theories of drinking and alcoholism (pp. 203–246). The Guilford Press. https://doi.org/10.1037/1040-3590.16.1.4
   Google Scholar
• Gu, B., Zhu, M., Glass, M. R., Rougié, M., Nikolova, V. D., Moy, S. S., Carney, P. R., & Philpot, B. D. (2019). Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice. The Journal of Clinical Investigation, 129(12), 12. https://doi.org/10.1172/JCI130419
   PubMed Web of Science ®Google Scholar
• Hall, W., & Solowij, N. (1998). Adverse effects of cannabis. The Lancet, 352(9140), 1611–1616. https://doi.org/10.1016/S0140-6736(98)05021-1
   PubMed Web of Science ®Google Scholar
• Haller, H., Cramer, H., Lauche, R., Gass, F., & Dobos, G. J. (2014). The prevalence and burden of subthreshold generalized anxiety disorder: A systematic review. BMC Psychiatry, 14(1), 128. https://doi.org/10.1186/1471-244X-14-128
   PubMedGoogle Scholar
• Iffland, K., & Grotenhermen, F. (2017). An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research, 2(1), 139–154. https://doi.org/10.1089/can.2016.0034
   PubMedGoogle Scholar
• Iuvone, T., Esposito, G., De Filippis, D., Scuderi, C., & Steardo, L. (2009). Cannabidiol: A promising drug for neurodegenerative disorders? CNS Neuroscience & Therapeutics, 15(1), 65–75. https://doi.org/10.1111/j.1755-5949.2008.00065.x
   PubMed Web of Science ®Google Scholar
• Jones, B. T., Corbin, W., & Fromme, K. (2001). A review of expectancy theory and alcohol consumption. Addiction, 96(1), 57–72. https://doi.org/10.1046/j.1360-0443.2001.961575.x
   PubMed Web of Science ®Google Scholar
• Karl, T., Garner, B., & Cheng, D. (2017). The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer’s disease. Behavioural Pharmacology, 28(2), 142–160. https://doi.org/10.1097/FBP.0000000000000247
   PubMed Web of Science ®Google Scholar
• Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. U. (2012). Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. International Journal of Methods in Psychiatric Research, 21(3), 169–184. https://doi.org/10.1002/mpr.1359
   PubMed Web of Science ®Google Scholar
• Khan, R., Naveed, S., Mian, N., Fida, A., Raafey, M. A., & Aedma, K. K. (2020). The therapeutic role of cannabidiol in mental health: A systematic review. Journal of Cannabis Research, 2(1), 1–21. https://doi.org/10.1186/s42238-019-0012-y
   Google Scholar
• Khantzian, E. J. (1987). The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence Allen, D.F. . In The cocaine crisis (pp. 65–74). Boston, MA.: Springer.
   Google Scholar
• Lai, H. M. X., Cleary, M., Sitharthan, T., & Hunt, G. E. (2015). Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic review and meta-analysis. Drug and Alcohol Dependence, 154, 1–13. https://doi.org/10.1016/j.drugalcdep.2015.05.031
   PubMed Web of Science ®Google Scholar
• Lovibond, P. F., & Lovibond, S. H. (1995). The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck depression and anxiety inventories. Behaviour Research and Therapy, 33(3), 335–343. https://doi.org/10.1016/0005-7967(94)00075-U
   PubMed Web of Science ®Google Scholar
• Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Crippa, A. S. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current Drug Safety, 6(4), 237–249. https://doi.org/10.2174/157488611798280924
   PubMedGoogle Scholar
• Metrik, J., Kahler, C. W., Reynolds, B., McGeary, J. E., Monti, P. M., Haney, M., De Wit, H., & Rohsenow, D. J. (2012). Balanced placebo design with marijuana: Pharmacological and expectancy effects on impulsivity and risk taking. Psychopharmacology, 223(4), 489–499. https://doi.org/10.1007/s00213-012-2740-y
   PubMed Web of Science ®Google Scholar
• Mojtabai, R., Olfson, M., Sampson, N. A., Jin, R., Druss, B., Wang, P. S., Wells, K. B., Pincus, H. A., & Kessler, R. C. (2011). Barriers to mental health treatment: Results from the National Comorbidity Survey Replication (NCS-R). Psychological Medicine, 41(8), 1751. https://doi.org/10.1017/S0033291710002291
   PubMed Web of Science ®Google Scholar
• Niles, A. N., Dour, H. J., Stanton, A. L., Roy-Byrne, P. P., Stein, M. B., Sullivan, G., Sherbourne, C. D., Rose, R. D., & Craske, M. G. (2015). Anxiety and depressive symptoms and medical illness among adults with anxiety disorders. Journal of Psychosomatic Research, 78(2), 109–115. https://doi.org/10.1016/j.jpsychores.2014.11.018
   PubMed Web of Science ®Google Scholar
• Norman, S. B., Inaba, R. K., Smith, T. L., & Brown, S. A. (2008). Development of the PTSD- alcohol expectancy questionnaire. Addictive Behaviors, 33(6), 841–847. https://doi.org/10.1016/j.addbeh.2008.01.003
   PubMed Web of Science ®Google Scholar
• Olatunji, B. O., Cisler, J. M., & Tolin, D. F. (2007). Quality of life in the anxiety disorders: A meta-analytic review. Clinical Psychology Review, 27(5), 572–581. https://doi.org/10.1016/j.cpr.2007.01.015
   PubMed Web of Science ®Google Scholar
• Osborne, J. W. (2013). Best practices in data cleaning. Sage.
   Google Scholar
• Plaisier, I., De Graaf, R., De Bruijn, J., Smit, J., Van Dyck, R., Beekman, A., & Penninx, B. (2012). Depressive and anxiety disorders on-the-job: The importance of job characteristics for good work functioning in persons with depressive and anxiety disorders. Psychiatry Research, 200(2–3), 382–388. https://doi.org/10.1016/j.psychres.2012.07.016
   PubMed Web of Science ®Google Scholar
• Ribeiro, A., Almeida, V. I., Costola-de-souza, C., Ferraz-de-paula, V., Pinheiro, M. L., Vitoretti, L. B., Gimenes-Junior, J. A., Akamine, A. T., Crippa, J. A., Tavares-de-lima, W., & Palermo-Neto, J. (2015). Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. Immunopharmacology and Immunotoxicology, 37(1), 35–41. https://doi.org/10.3109/08923973.2014.976794
   PubMed Web of Science ®Google Scholar
• Russo, E. B. (2017). Cannabidiol claims and misconceptions. Trends in Pharmacological Sciences, 38(3), 198–201. https://doi.org/10.1016/j.tips.2016.12.004
   PubMed Web of Science ®Google Scholar
• Scott, K. M., Bruffaerts, R., Tsang, A., Ormel, J., Alonso, J., Angermeyer, M. C., Benjet, C., Bromet, E., De Girolamo, G., De Graaf, R., Gasquet, I., Gureje, O., Haro, J. M., He, Y., Kessler, R. C., Levinson, D., Mneimneh, Z. N., Browne, O., Gasquet, I., Von Korff, M., & Posada-Villa, J. (2007). Depression–anxiety relationships with chronic physical conditions: Results from the World Mental Health surveys. Journal of Affective Disorders, 103(1–3), 113–120. https://doi.org/10.1016/j.jad.2007.01.015
   PubMed Web of Science ®Google Scholar
• Scuderi, C., Filippis, D. D., Iuvone, T., Blasio, A., Steardo, A., & Esposito, G. (2009). Cannabidiol in medicine: A review of its therapeutic potential in CNS disorders. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives, 23(5), 597–602. https://doi.org/10.1002/ptr.2625
   Google Scholar
• Slavin, M., Barach, E., Farmer, S., Luba, R., & Earleywine, M. (2017). Cannabis and symptoms of PMS and PMDD. Addiction Research & Theory, 25(5), 383–389. https://doi.org/10.1080/16066359.2017.1294165
   Web of Science ®Google Scholar
• Spinella, T. C., Stewart, S. H., Naugler, J., Yakovenko, I., & Barrett, S. P. (2021). Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: A randomized crossover study. Psychopharmacology, 238(7), 1965–1977. https://doi.org/10.1007/s00213-021-05823-w
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. (2019). Key substance use and mental health indicators in the United States: Results from the 2018 national survey on drug use and health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
   Google Scholar
• Tran, T., & Kavuluru, R. (2020). Social media surveillance for perceived therapeutic effects of cannabidiol (CBD) products. International Journal of Drug Policy, 77, 102688. https://doi.org/10.1016/j.drugpo.2020.102688
   PubMed Web of Science ®Google Scholar
• Zuardi, A. W., De Souza Crippa, J. A., Hallak, J. E. C., Campos, A. C. D., & Guimarães, F. S. (2017). The anxiolytic effects of cannabidiol (CBD) V.R. Preedy . In Handbook of cannabis and related pathologies (pp. e131–e139). Academic Press.
   Google Scholar